Background The widespread use of immune checkpoint inhibitor (ICI)–based combinations as first-line therapy for metastatic renal cell carcinoma (mRCC) has created an unmet need for effective treatment options at disease progression. Cabozantinib is recommended after ICI failure; however, real-world evidence regarding i...
A. Bamias, Michael Liontos, I. Binas et al.· Cancer Management and Resear...· 0 citations
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 agents, exhibit notable efficacy across various types of cancer. Nevertheless, they can trigger immune-related adverse events, among which immune-mediated liver injury (ILICI) occurs in 5-10% of patients. Corticosteroids are currently recommended...
M. Kyrkasiadou, A. Kyriazoglou, I. Kotsantis et al.· Experimental and Therapeutic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.